Navigation Links
Amgen Announces 2013 Second Quarter Dividend
Date:3/6/2013

our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments (domestic or foreign) involving current and future products, sales growth of recently launched products, competition from other products (domestic or foreign) and difficulties or delays in manufacturing our products. In addition, sales of our products are affected by reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and health care cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We, or others, could identify safety, side effects or manufacturing problems with our products after they are on the market.  Our business may be impacted by government investigations, litigation and product liability claims. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, we compete with other
'/>"/>
SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
3. Amgen Announces 2012 First Quarter Dividend
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Acquire Micromet
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Amgen Announces 2012 Third Quarter Dividend
10. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
11. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 16, 2014  Vermillion, Inc. (NASDAQ: ... gynecologic disease, today announced the next step in its ... bio-analytics solutions provider with the naming of current Chief ... Chief Executive Officer, while current Chairman of the Board ... serve as Chairman. These changes are effective January 1, ...
(Date:12/17/2014)... , Dec. 17, 2014   Synageva BioPharma Corp. ... developing therapeutic products for rare disorders, announced today its ... held in San Francisco, CA. ... Chief Executive Officer, will present on Monday, January 12, ... presentation will be webcast live and may be accessed ...
(Date:12/15/2014)... YORK , Dec. 15, 2014  GlassesOff Inc. ... Yuval Bar-Gil as an independent director of the ... founder of AeroScout and served as its CEO until ... in 2012, a $240 million transaction. Recognized as the ... Mr. Bar-Gil,s leadership, AeroScout provided Wi-Fi -based RFID solutions ...
(Date:12/13/2014)... , Dec. 12, 2014 /CNW/ - MaRS and Virgin ... today that they have joined forces to support Canadian entrepreneurs ... , Virgin Group Founder was at the MaRS Centre to ... new, national impact venture fund. This fund has $1 million ... Vancouver -based Mindset Social Innovation Foundation, founded ...
Breaking Biology Technology:Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3MaRS and Virgin Unite partner to invest in business as a force for good 2MaRS and Virgin Unite partner to invest in business as a force for good 3
... On June 27, 2008,GeneraMedix Inc. received approval ... its Epoprostenol for Injection 1.5 mg New Drug,Application ... indicated for the long-term,intravenous treatment of primary pulmonary ... of disease in NYHA,Class III and Class IV ...
... Advanced Life Sciences,Holdings, Inc. (Nasdaq: ... the,discovery, development and commercialization of novel drugs ... respiratory diseases, today,announced that it was added ... Investment Group reconstituted its comprehensive set of ...
... July 3 Senesco,Technologies, Inc. ("Senesco" or the ... has contracted with Polyplus-transfection (Illkirch, France) to,supply Polyplus,s ... of siRNA against Factor 5A and a plasmid ... reported positive preclinical in vivo results,using its combination ...
Cached Biology Technology:GeneraMedix Inc. Receives Approval for Epoprostenol for Injection 1.5 mg 2Advanced Life Sciences Added to Russell Microcap Index 2Advanced Life Sciences Added to Russell Microcap Index 3Senesco Signs a Supply Agreement for Polyplus-transfection's Delivery System 2Senesco Signs a Supply Agreement for Polyplus-transfection's Delivery System 3Senesco Signs a Supply Agreement for Polyplus-transfection's Delivery System 4
(Date:11/18/2014)...  The Secure Identity & Biometrics Association (SIBA) ... the formation of The Airport Entry and Exit ... and Biometric Entry and Exit Solutions Framework for ... from BORDERPOL, the international non-profit organization that works ... regarding border security, traveler and migration systems. ...
(Date:11/15/2014)... 13, 2014  While we may still be a few ... in "Star Trek" to gain instant access to all that ... with smartphones and tablets for monitoring and measuring our health ... This may seem a tad Orwellian to some, but a ... of these technological opportunities into their healthcare regime. ...
(Date:11/7/2014)... Debra Auguste, associate professor, biomedical engineering, in the ... of New York, have identified a molecule that ... the most aggressive forms of breast cancer. , ... mortality rate owing to aggressive proliferation and metastasis ... Professor Auguste,s team, discovered the overexpression of intercellular ...
Breaking Biology News(10 mins):Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4
... the body's normally protective inflammation response can drive some ... discovering an apparent trigger to this potentially deadly process. ... blood cells, or leukocytes, engulf and destroy invading microbes ... serum in the blood -- often an antibody produced ...
... newly discovered genetic threads in the rich tapestry of ... Cancer Center team has dramatically killed brain cancer cells ... experimental antitumor drug. , The unlikely pairing of cholesterol-lowering ... grown in the laboratory. By contrast, using either ...
... University and pediatric specialists at Baylor College of Medicine have ... as passkeys that allows drugs to enter cancer cells. , ... journal Organic and Biomolecular Chemistry. , All living cells ... or membranes, form a protective cocoon around the cell's inner ...
Cached Biology News:Antibody signal may redirect inflammation to fuel cancer 2Antibody signal may redirect inflammation to fuel cancer 3Statin plus cancer drug deliver combo punch to brain cancer cells 2Buckyballs used as 'passkey' into cancer cells 2
Rabbit polyclonal to Somatostatin 28 ( Abpromise for all tested applications). entrezGeneID: 6750 SwissProtID: P61278...
... well Magnetic-Ring Stand is designed for paramagnetic ... microplates. The stand has a plastic base ... plate footprint. The use of 96 extremely ... easy magnetic separation. With this magnetic stand, ...
... DNA polymerase from Thermus aquaticus expressed in ... 1 tube of 250 units enzyme/tube and ... DNA), is the same enzyme as AmpliTaq ... a proprietary separation process to ensure that ...
Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/L; 1 tube of 1, 000 units enzyme/tube w/Buffer II and MgCl2...
Biology Products: